You are here


MorphoSys AG (FSE: MOR; Standard Segment, TecDAX) is today one of the world’s leading biotechnology companies. From a pure antibody platform enterprise MorpoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model.

In addition to therapeutic antibodies, MorphoSys strives to complement its technology platform by securing access to new markets and molecule classes. The technology alliance and equity investment in Lanthio Pharma, which was signed in 2012, was part of this Innovation Capital Initiative.